Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine

Rafael Rosell, Laura Bonanno, Miquel Taron

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lung cancer driven by EGF receptor (EGFR)-sensitizing mutations is a new entity that requires a molecular diagnosis. Screening for EGFR mutations should be mandatory in lung cancer tumors for never-smokers regardless of histology, also in adenocarcinomas and large-cell carcinomas regardless of smoking history. EGFR mutations are more frequently found in women than men. Response to EGFR tyrosine kinase inhibitors in patients with EGFR mutations is very high with significant improvement in progression-free survival. However, the duration of progression-free survival is unpredictable at the individual level. Genetic modifiers, such as the BRCA1/NFKBIA mRNA expression could greatly predict the duration of response and pave the way for development of novel therapeutic interventions.

Original languageEnglish
Title of host publicationEGFR Inhibitors in Cancer Treatment
PublisherFuture Medicine Ltd.
Pages19-32
Number of pages14
ISBN (Print)9781780840260, 9781780841137
DOIs
Publication statusPublished - Jan 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine'. Together they form a unique fingerprint.

Cite this